Inquiry Basket
Loading ......
Foot-and-mouth disease (FMD) remains one of the most economically devastating infectious diseases affecting livestock worldwide. Caused by the foot-and-mouth disease virus (FMDV), this highly contagious pathogen infects cloven-hoofed animals such as cattle, swine, sheep, goats, and buffalo, resulting in the death of young animals and the reduced productivity of adult animals, which leading to severe production losses and trade restrictions.
Despite decades of control efforts, FMD continues to persist in large regions of Asia, Africa, and the Middle East, posing an ongoing threat to both endemic and disease-free countries.
Vaccination has been the cornerstone of FMD control strategies. However, the high genetic variability of FMDV, combined with limitations of traditional vaccines, has driven the development of next-generation vaccine technologies. These innovations are transforming the landscape of FMD prevention and opening new opportunities for improved efficacy, safety, and scalability.
FMDV is a member of the Picornaviridae family, with a positive-sense single-stranded RNA genome of approximately 8,000 nucleotides.
The viral genome encodes a polyprotein that is processed into:
Among these, VP1 is the most immunogenic protein, containing critical neutralizing epitopes such as the G-H loop with the RGD motif responsible for host cell receptor binding.
A major challenge in vaccine development arises from the existence of seven distinct serotypes (O, A, C, SAT1–3, Asia-1), with limited cross-protection between them.
This antigenic diversity necessitates:
Fig. 1 Production and processing of FMDV proteins.
Inactivated whole-virus vaccines have long served as the cornerstone of foot-and-mouth disease control programs worldwide. The most widely used commercial FMD vaccines are inactivated whole-virus vaccines, which have been used since the mid-20th century. The immunogenicity of these vaccines is highly dependent on the structural integrity of viral particles, particularly the intact 146S virions, which represent the most protective antigenic form.
These vaccines played a critical role in reducing FMD incidence in Europe and other regions.
However, several drawbacks limit their long-term effectiveness:
Large-scale propagation of infectious FMDV requires high-level biocontainment facilities, increasing operational complexity and the risk associated with accidental release.
The most immunogenic 146S particles are inherently unstable and can readily dissociate into 12S pentameric subunits under moderate temperatures or mildly acidic conditions. These degraded forms exhibit significantly reduced immunogenicity, making particle stability a critical factor during vaccine production, storage, and transport.
In addition to 75S empty capsids, further dissociation into pentamers can expose internal epitopes that preferentially induce non-neutralizing antibodies, thereby reducing overall vaccine efficacy.
Due to the presence of seven distinct serotypes, including particularly unstable types such as O and SAT, vaccines must be carefully matched and frequently updated to ensure effectiveness.
Maintaining the structural integrity of 146S particles requires strict temperature control, as even mild environmental stress can accelerate degradation into less protective forms.
As a result, there is a strong need for safer and more versatile vaccine platforms.
Although inactivated virus vaccines are recommended by the OIE for the control and eradication of FMD, there are still some deficiencies in vaccine production that lead to sporadic and even severe outbreaks of FMD. Virus-like particles (VLPs) are large particles composed of one or several structural proteins of the virus which do not contain viral nucleic acid and cannot replicate, and have an overall structure similar to that of virus particles. As an ideal substitute for the traditional inactivated virus in vaccine production, VLPs not only retain the spatial conformation of natural virus particles with epitopes that stimulate the production of neutralizing antibodies, but also have certain safety.
The repetitive and highly ordered surface structure of VLPs promotes efficient uptake by antigen-presenting cells, particularly dendritic cells, enhancing antigen processing and presentation.
By preserving conformational epitopes, VLPs are capable of inducing high titers of neutralizing antibodies comparable to those elicited by intact virus particles, which are essential for protective immunity.
VLPs avoid risks associated with infectious virus handling and can be engineered for enhanced stability, reducing degradation into less immunogenic forms during storage and distribution.
Empty capsid structures can be generated directly within the vaccinated host through delivery of capsid-encoding genes using viral vectors such as adenoviruses. This approach enables endogenous antigen production and can enhance immune responses by mimicking natural infection processes.
VLPs can be produced in various expression platforms, including bacteria, mammalian cells, insect cells, and plant-based systems. These particles are then purified and administered as vaccines, allowing precise control over antigen quality, assembly, and dosage.
Efficient VLP formation depends on proper cleavage of precursor proteins (e.g., P1-2A) by proteases such as 3C, as well as optimized expression conditions that support correct folding and assembly of capsid proteins.
Targeted mutations and sequence modifications can be introduced to improve inter-subunit interactions within the capsid, enhancing resistance to thermal or chemical stress and maintaining antigen integrity.
Synthetic peptide vaccines represent a highly targeted approach to immunization, focusing on defined antigenic regions rather than whole proteins or viral particles. By synthesizing peptides corresponding to these critical regions, researchers can design vaccines that elicit specific immune responses while minimizing unnecessary antigenic components. This approach offers significant flexibility and enables rapid adaptation to emerging viral variants.
G-H loop (RGD motif): FMDV is recognized by its RGD motif (amino acid residue 130–160), which is the host cell integrin receptor binding site and plays an important role in the production of neutralizing antibodies to FMDV.
T-cell epitopes in VP4 (internal, highly conserved, amino acid residue 20–34) and other proteins: These epitopes are easy to express in peptide vaccines and the epitope sequence can be changed to represent the appropriate strain in an epidemic scenario.
Synthetic peptides do not contain infectious material or replicative elements, eliminating biosafety concerns associated with live virus handling and making them suitable for large-scale production without high-containment facilities.
Multiple epitopes from different serotypes or proteins can be combined into a single construct, improving the potential for broader immune coverage when properly formulated.
Short linear peptides often lack the structural complexity required to efficiently stimulate strong immune responses, particularly in the absence of conformational epitopes present in native viral particles.
To achieve sufficient immunogenicity, peptide vaccines typically require potent adjuvants or advanced delivery platforms, which can increase formulation complexity and variability in immune outcomes.
Immune responses to peptide epitopes can be influenced by host genetic background, including MHC restriction, which may lead to inconsistent protection across different animal populations.
The first peptide vaccines represented single linear epitopes. More recently, the multiple-antigen peptide system (MAP) has been developed. MAPs are dendritic polymers with lysine dendrimers exposed as core and dendritic arms with multiple antigenic epitopes. This dendritic peptide copolymer is more immunogenic than a simple linear juxtaposition of B and T epitopes and is moderately resistant to enzyme digestion. In contrast, VP1 is degraded easily by trypsin.
Fig. 2 A multiple-antigen peptide (MAP) system model.
Despite technological advances, several challenges remain:
Antigenic Diversity: Limited cross-protection between serotypes requires multivalent or strain-matched vaccines.
Duration of Immunity: Current vaccines often require repeated dosing to maintain protection.
Manufacturing and Biosafety: Safe, scalable production systems are essential for global deployment.
At Creative Diagnostics, we provide a comprehensive portfolio of high-quality FMD-related antigens and antibodies designed to accelerate vaccine development and immunological research.
Our Product Offerings Include:
All products are developed under strict quality control standards to ensure:
The development of foot-and-mouth disease vaccines has evolved significantly, from traditional inactivated virus vaccines to advanced platforms such as VLPs, peptide vaccines, and viral vectors. These innovations are addressing longstanding challenges in safety, efficacy, and adaptability.
However, continued progress depends on a deep understanding of viral structure, immune mechanisms, and antigenic diversity—supported by reliable and high-quality research reagents. By enabling precise antigen design and robust immune evaluation, we are committed to supporting global efforts to control and ultimately eradicate foot-and-mouth disease.
Loading ......
